Bio View Stock Net Asset

BIOV Stock  ILS 28.90  0.10  0.35%   
Bio View fundamentals help investors to digest information that contributes to Bio View's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio View's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio View stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bio View Company Net Asset Analysis

Bio View's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Net Asset

 = 

Current Market Value

-

Current Liabilities

More About Net Asset | All Equity Analysis

Current Bio View Net Asset

    
  40.02 M  
Most of Bio View's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio View is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition

Based on the recorded statements, Bio View has a Net Asset of 40.02 M. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all Israel stocks is notably lower than that of the firm.

Bio Net Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio View's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio View could also be used in its relative valuation, which is a method of valuing Bio View by comparing valuation metrics of similar companies.
Bio View is currently under evaluation in net asset category among its peers.

Bio Fundamentals

About Bio View Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bio View's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio View using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio View based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Bio Stock

Bio View financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio View security.